Iron Polymaltose Complex Syrup: API Specs for Liquids
Formulators working on oral iron products know that not all iron APIs behave the same way in a liquid base. Iron polymaltose complex syrup falls into a distinct formulation category: a macromolecular ferric complex absorbed through active transport rather than passive ionic diffusion. This distinction matters at every stage, from API specification to finished-product stability testing. Getting the API right means understanding the molecular weight distribution, iron content, and coordination chemistry that determine how the complex performs in a patient’s gastrointestinal tract.
In this blog, you will find a structured breakdown of the API specifications, stability factors, and regulatory documentation requirements that define a technically sound iron polymaltose complex syrup.
Key Takeaways
- Iron polymaltose complex syrup delivers approximately 10 to 15% oral iron absorption through a self-regulating active transport mechanism.
- The polymaltose ligand quality directly determines release kinetics, tolerability, and clinical consistency across the finished oral liquid product.
- API specifications must cover molecular weight distribution around 55 kD, along with standard assay, pH, and microbial limit parameters.
Quick Answer: Iron polymaltose complex syrup API specifications must address elemental iron content of about 27% by mass, a molecular weight around 55 kD, batch-consistent polymaltose coordination, and ICH-compliant stability data for oral liquid formulations.
What Iron Polymaltose Complex Syrup Is and How It Works
Iron polymaltose complex syrup is an oral iron formulation in which a ferric hydroxide core is surrounded by polymaltose chains. This macromolecular structure distinguishes it fundamentally from ionic iron salts such as ferrous sulfate. Iron is not released as free ions in the gastrointestinal tract.
Instead, the intestinal mucosa absorbs iron through active transport. Absorption is self-regulating: it increases with greater iron deficiency and decreases as iron stores normalise. Oral absorption is approximately 10 to 15% of the administered dose, with maximum absorption capacity reached within 30 minutes of ingestion. [1]
The complex carries a molecular weight of approximately 55 kD, with the active substance containing about 27% iron by mass. [2] The standard finished-product concentration is 10 mg elemental iron per mL.
For formulators and iron polymaltose API manufacturers, polymaltose ligand quality directly determines release kinetics, tolerability, and clinical consistency across patient populations.
Clinical Uses of Iron Polymaltose Complex Syrup
Iron polymaltose complex syrup is indicated for the treatment and prevention of iron deficiency anaemia in neonates, children, pregnant women, and adults with documented iron deficiency, with or without anaemia.
Paediatric Use
Dosing is weight-based. Premature infants receive 2.5 to 5 mg/kg daily. Children up to one year receive 25 to 50 mg elemental iron daily. Children aged one to twelve receive 50 to 100 mg daily. A four-month paediatric trial found haemoglobin increases of 2.3 g/dL with iron polymaltose versus 3.0 g/dL with iron sulfate, with significantly fewer gastrointestinal side effects in the polymaltose group. [3]
Use in Pregnancy
The standard dose for pregnant women is 100 to 300 mg elemental iron per day. A 90-day trial showed a haemoglobin increase of 2.16 g/dL with iron polymaltose complex versus 1.93 g/dL with iron sulfate. Side effects were reported in 29.3% versus 56.4% of participants, respectively, a clinically meaningful tolerability advantage in a population prone to early discontinuation. [3]
API Specifications for Iron Polymaltose Complex Syrup
The API specifications for iron polymaltose complex syrup must address the unique physicochemical properties of a macromolecular iron carbohydrate complex rather than a simple ionic salt. Standard API release specifications for iron polymaltose cover identity, assay, iron content, molecular weight distribution, oral solution pH, colour, and microbial limits.
Identity and Assay
- Identity confirmation by infrared spectroscopy and iron-specific colourimetric assay
- Elemental iron content specified as a percentage of labelled claim, typically 95.0 to 105.0% of stated iron per mL
- Active substance iron content: approximately 27% iron by mass of the dried complex [2]
- Polymaltose chain characterisation by gel permeation chromatography to confirm molecular weight distribution around 55 kD [2]
Physical Parameters
- Appearance: dark brown to black viscous liquid, free from visible particulates
- Specific gravity: assessed to confirm iron concentration consistency per batch
- Viscosity: controlled within defined limits to ensure dose accuracy in 5 mL measuring doses
Microbial Limits and pH
- Total aerobic microbial count and absence of specified organisms per BP or USP oral liquids monograph
- pH of the reconstituted or ready-to-use oral solution: assessed for consistency with the physiological range supporting mucosal tolerance
- Preservative content assay for methyl and propyl hydroxybenzoate when present in the formulation
For iron polymaltose API manufacturers supplying finished-dose manufacturers, the molecular weight distribution specification is the most technically differentiating parameter in the entire API release package.
Stability Factors in Iron Polymaltose Complex Syrup
The stability of iron polymaltose complex syrup depends on the integrity of the iron-polymaltose coordination bond, the pH of the liquid base, light exposure, and thermal stress during storage and distribution.
pH Stability
The ferric hydroxide core is stable across the broad pH range typical of oral liquid formulations. Strongly acidic conditions can disrupt the coordination structure, release free ionic iron, and alter the finished product’s absorption profile. Maintaining pH within the formulation design space is a critical process parameter for both API manufacturers and finished-dose formulators. [1]
Light and Temperature
Store iron polymaltose complex syrup below 25°C and protect it from direct light. Amber glass or amber PET packaging is standard to prevent photodegradation of the iron-carbohydrate complex. Under these conditions, confirmed shelf life is 36 months from the manufacturing date. [2]
Excipient Interactions
- Sorbitol solution (70%) and sucrose are established co-solvents supporting physical stability of the syrup base
- Methyl and propyl hydroxybenzoate preservatives are compatible with the iron complex at standard use concentrations
- Mixing with fruit or vegetable juices may cause slight colour change without affecting stability or efficacy [2]
- Do not co-administer injectable iron with oral iron polymaltose complex syrup because it may cause an additive iron load.
What Iron Polymaltose API Manufacturers Must Supply
Finished-dose manufacturers sourcing iron polymaltose complex syrup API require a documentation package covering both chemical characterisation and manufacturing process controls that ensure batch-to-batch consistency. Iron polymaltose API manufacturers supplying regulated markets must provide this in a format supporting CDSCO, WHO, EU, or US regulatory submissions.
Technical Documentation Requirements
Iron polymaltose API manufacturers must supply the following per production batch and within the drug master file:
- Certificate of analysis covering identity, assay, iron content, molecular weight, pH, appearance, microbial limits, and heavy metals
- Stability data package per ICH Q1A with real-time and accelerated studies at 25°C/60% RH and 40°C/75% RH
- Synthesis route documentation covering the iron source, polymaltose preparation method, and complexation process controls
- Genotoxic impurity risk assessment per ICH M7 for all reagents used in the polymaltose synthesis step
- Residual solvent analysis per ICH Q3C wherever organic solvents are used during manufacturing
GMP and Regulatory Standing
Iron polymaltose API manufacturers supplying oral liquid formulations must hold WHO-GMP or equivalent certification. EU market supply requires an ASMF or CEP from EDQM. US NDA or ANDA products require a valid FDA DMF. Finished-dose manufacturers must audit API site GMP status at a defined review interval and confirm current regulatory standing before each procurement cycle.
Final Thoughts
Iron polymaltose complex syrup is one of the more technically demanding oral iron APIs to source correctly, precisely because its clinical performance depends on the structural integrity of the iron-polymaltose coordination bond. Start by requesting a full certificate of analysis that includes molecular weight distribution data, not just elemental iron content, because the two tell different parts of the same quality story. Verify that your supplier holds a current WHO-GMP or equivalent certification and can provide an ICH Q1A-compliant stability package covering both real-time and accelerated conditions.
Review the API manufacturer’s DMF or ASMF status before each procurement cycle to ensure regulatory standing is current for your target market. Formulators who build these requirements into their approved vendor criteria from the outset and choose an API brand like WBCIL with documented GMP standing and multi-market regulatory filings protect both product quality and regulatory timelines.
- Geisser P, Burckhardt S. The Pharmacokinetics and Pharmacodynamics of Iron Preparations. Pharmaceutics. 2011;3(1):12–33.
- Maltofer Syrup Data Sheet. Medsafe New Zealand.
- Toblli JE, Brignoli R. Iron(III)-Hydroxide Polymaltose Complex in Iron Deficiency Anaemia. Arzneimittelforschung. 2007;57(6):431–438.
Iron polymaltose complex syrup treats and prevents iron deficiency anaemia in infants, children, pregnant women, and adults. The syrup form is preferred where tablets are unsuitable, particularly in paediatric patients and during pregnancy, where tolerability and compliance matter most.
The standard concentration is 10 mg elemental iron per mL. Premature infants receive 2.5 to 5 mg per kg daily. Children up to one year receive 25 to 50 mg daily. Children aged one to twelve receive 50 to 100 mg daily. Adults and pregnant women receive 100 to 300 mg daily.
The primary factors are pH, temperature, and light exposure. Store below 25°C in amber packaging. Under recommended conditions, shelf life is confirmed at 36 months. Strongly acidic conditions can disrupt the iron-polymaltose coordination bond and alter the absorption profile.
Iron polymaltose delivers iron as a stable macromolecular complex absorbed through active transport, not as free ionic iron. In a 90-day clinical trial in pregnant women, 29.3% of iron polymaltose recipients reported side effects versus 56.4% of iron sulfate recipients.
Verify the certificate of analysis includes molecular weight distribution around 55 kD alongside standard assay and microbial limits. Confirm WHO-GMP certification, an ICH Q1A-compliant stability package, and a valid DMF or ASMF for the target regulated market.
